| | [Survey] Bioavailability Toolkit Share insight on the drug developer’s perspective on bioavailability enhancement technologies and the reasoning behind the use of certain technologies in preclinical and early-stage clinical development. Take survey. |
| Sanofi CEO Paul Hudson laid out aggressive plans to reshape the company and slim down management last December. Now, the French pharma giant has bid farewell to four top executives, including its combination chief medical and digital officer, Ameet Nathwani. But building Sanofi’s future tech will still be a priority, with Hudson saying he’d prefer to have a single, dedicated digital leader on the team. Elsewhere, Sanofi’s C-suite offered more details on the “simplification” of its tie-ups with Regeneron over the past year. Those stories and our top reads of the week are below. | |
|
Featured Story | | | Wednesday, February 12, 2020 Sanofi bid farewell to four top executives as new CEO Paul Hudson rejigs and simplifies the company's management structure. Part of the plan? Separating the roles of chief medical officer and chief digital officer, so Sanofi can accelerate its bid to incorporate AI and other new technologies companywide. |
|
|---|
|
Top Stories Of The Week Friday, February 7, 2020 It’s been a busy year for Sanofi: It’s been rejigging deals with the likes of Regeneron and bought out a biotech in the form of Synthorx. Tuesday, February 11, 2020 Every year, new drugs enter the market, but only a select few come bearing blockbuster potential. For the 2020 crop, 11 are expected to cross the $1 billion annual sales threshold by 2024. They span several therapeutic areas, including CNS, oncology, hematology, inflammatory diseases and metabolic disorders. Thursday, February 6, 2020 A research team led by the University of Oxford has discovered a molecular “first responder” in endothelial cells that detects blood-flow stress. Targeting the shape of this force detector could reduce harmful plaques in arteries and therefore holds promise for preventing serious heart diseases, they argue. Wednesday, February 12, 2020 The FDA has cleared the world’s first portable MRI system, designed to be wheeled to a hospital bedside for scanning a patient’s head and brain. Wednesday, February 12, 2020 Gilead's experimental remdesivir has emerged as the most promising candidate against the deadly new coronavirus. But some unexpected confusion has cropped up about its China patent—the latest being a Chinese firm claiming it's successfully copied the drug and started mass production. Tuesday, February 11, 2020 At last year’s American Society of Clinical Oncology meeting, both Novartis and Merck KGaA rolled out data for their drugs aimed at MET exon 14 skipping-mutated non-small cell lung cancer. Now thanks to an FDA priority review for capmatinib, Novartis is one step ahead. Monday, February 10, 2020 Anti-amyloid beta antibodies in development at Eli Lilly and Roche have failed to improve outcomes in a phase 2/3 Alzheimer’s disease trial. Despite the setback, Roche is continuing two phase 3 trials of its asset in a broader population of Alzheimer’s patients. Wednesday, February 12, 2020 Back in 2018, Bayer mulled outsourcing R&D as part of a greater restructuring. Now, the company is pulling the trigger on that plan, transferring 400 staffers to a “full-fledged research center” to be set up by Nuvisan, a German CRO, in Berlin. The deal is slated to close by the middle of this year. Monday, February 10, 2020 Dr. Reddy’s has spent nearly five years trying to get out from under a warning letter for an important API plant in India but has yet to shake off all of the FDA’s concerns. In fact, a new FDA filing raises new concerns about out-of-spec drugs and cleaning of solvents off equipment at the plant. Monday, February 10, 2020 Hoping to improve the durability of CAR-T treatments in multiple myeloma, University of Utah researchers created a CAR-T that targets both cancer cells and cancer stem cells using an antibody against the surface molecule CD229. It produced promising results in mouse models of the disease, as well as samples taken from multiple myeloma patients. Tuesday, February 11, 2020 It’s all about the lips in Allergan’s latest Juvederm campaign. In its first consumer effort focused on lip treatments, Allergan looks to especially target millennials with a natural—but individual—choice to create the lips they want. Why now? Because millennials have flipped the script when it comes to facial aesthetics, getting into fillers like Juvederm before neurotoxins such as Botox. Resources Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: Quotient Sciences Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. | 